Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis

•Approximately one in four multiple sclerosis (MS) patients initiated high-efficacy disease-modifying agents (heDMAs).•Both demographic and clinical factors influenced the selection of heDMA for MS.•Study findings have important implications for understanding the differential factors for selecting a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2024-11, Vol.91, p.105896, Article 105896
Hauptverfasser:	Li, Jieni, Hutton, George J., Varisco, Tyler J., Lin, Ying, Essien, Ekere J., Aparasu, Rajender R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Disease-modifying agents Female Humans Immunologic Factors - administration & dosage Immunologic Factors - pharmacology Immunomodulating Agents - pharmacology Male Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Retrospective Studies Treatment selection Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!